Latest News From Pharmachem

    October 2014

  • Pfizer and Kyowa Hakko Kirin to collaborate on immuno-oncology combination study

    01 October, 2014

    Pfizer Inc. (NYSE:PFE) and Kyowa Hakko Kirin (Tokyo:4151), have entered into an agreement to explore the therapeutic potential of the combination of Pfizer's PF-05082566, an investigational, fully humanized monoclonal antibody (mAb) that stimulates signaling through 4-1BB (CD-137), a protein involved in regulation of immune cell activation, proliferation and survival, with Kyowa Hakko Kirin's anti-CCR4 antibody mogamulizumab

    Continue Reading »

  • The sterilisation principles

    01 October, 2014

    We are looking for a provider to deliver The sterilisation principles course. If you can deliver this programme could you please contact Cora on 0871245950.

    Continue Reading »

  • Probiotic yogurt could help protect against heavy metal poisoning

    09 October, 2014

    New research shows probiotic yogurt can reduce the uptake of certain heavy metals and environmental toxins by up to 78% in pregnant women. Led by Scientists at Lawson Health Research Institute's Canadian Centre for Human Microbiome and Probiotic Research, this study provides the first clinical evidence that a probiotic yogurt can be used to reduce the deadly health risks associated with mercury and arsenic.

    Continue Reading »

  • Limerick firm sold for $150 million after three years

    16 October, 2014

    A Limerick-based medical technology company founded just three years ago has been sold for about $150 million (€117 million). New York Stock Exchange- listed Becton Dickinson (BD) acquired GenCell Biosystems, founded by 34-year-old Kieran Curran, on Monday.

    Continue Reading »

  • Protecting us from our cells

    23 October, 2014

    Our immune system defends us from harmful bacteria and viruses, but, if left unchecked, the cells that destroy those invaders can turn on the body itself, causing auto-immune diseases like type-1 diabetes or multiple sclerosis. A molecule called insulin-like growth factor-1 (IGF-1) boosts the body's natural defence against this 'friendly fire', scientists at the European Molecular Biology Laboratory (EMBL) in Monterotondo, Italy, have found. The findings, published today in EMBO Molecular Medicine, are especially exciting because IGF-1 is already approved for use in patients, which could speed up the move to clinical trials for treating auto-immune diseases.

    Continue Reading »